NCT03778541: HFSRT With Concurrent TMZ for Large BMs

NCT03778541
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Chemotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with more than 3 brain metastases
https://ClinicalTrials.gov/show/NCT03778541

Comments are closed.

Up ↑